peroxidase (HRP). The other detection methods are the dot blot and immunoprecipitation assays, which respectively utilizes the phage that is immobilized onto either nitrocellulose membrane, or cyanogen bromide (CNBr) activated agarose.
Phage display technology is efficient in generating large numbers of diverse peptides and proteins, and selects the molecules that perform useful functions (Lowman, 1997) . A fusion M13 bacteriophage that interacts with HBcAg was isolated from a phage display cyclic peptide library (Ho et al., 2003) . The phage interacts tightly to HBcAg and the free peptide in the absence of the gpIII protein inhibited the association of HBcAg and L-HBsAg thus blocking the assembly of HBV. The binding of the fusion phage to HBcAg is believed to be on a specific region of amino acids at the protruding spikes of the core particles (Ho et al., 2003) . Phage bearing the sequence WSFFSNI has the potential to be further developed as an immunodiagnostic marker that can be used in immunoassays for example, ELISA and dot blot analyses. Such recombinant phages may potentially replace monoclonal antibodies used in HBV diagnosis. This type of phagebased diagnostic reagent can save time, cost and energy required to produce monoclonal antibodies. Therefore, the objective of this study was to establish assays for detecting HBcAg using the fusion phage.
Materials and Methods
Preparation and purification of HBcAg. Expression of full-length HBcAg in Escherichia coli cells and the purification of HBcAg with sucrose gradient centrifugation were done as described by Dyson and Murray (1995) and Tan et al. (1999) . Purified HBcAg was analyzed with SDS-PAGE and immunoblotting. The protein concentration was determined using the Bradford assay (Bradford, 1976) .
Large scale preparation and purification of M13 bacteriophage. Recombinant bacteriophage was propagated in Escherichia coli ER2738 grown in Luria Bertani (LB) medium. The cells were precipitated by centrifugation at 15,000ϫg for 5 min at 4°C and the phage in the supernatant was precipitated with PEG/NaCl [20% (w/v) in 2.5 M NaCl; 0.15 volume] overnight at 4°C. Purification of the phage was carried out with CsCl density gradient centrifugation as described by Smith and Scott (1993) . The amount of phage was determined by titration as plaque forming units (pfu).
Phage-enzyme-linked immunosorbent assay (phage-ELISA). Different amount of HBcAg (10 ng to 1 mg; 120 ml) was coated onto U-shaped high binding microtiter plate wells for 16 h and blocked with 10% milk diluent for 2 h at 4°C. The wells were washed three times with Tris Buffer Saline [TBS; Tris-HCl (50 mM, pH 7.5), NaCl (150 mM)] supplemented with 0.05% of Tween 20 (TBST), 5 min for each washing. The wells were then added with different concentration of purified fusion phage (1.0ϫ10 10 , 1.0ϫ10 11 and 1.0ϫ10 12 pfu/ml; 100 ml). After 1 h of incubation at room temperature, the wells were washed three times with TBST and anti-M13 monoclonal antibody conjugated with horseradish peroxidase (HRP, Amersham Pharmacia Biotech, 1 : 5,000; 200 ml) was added into the wells for another hour. Unbound antibodies were washed off using TBST and the substrate, 2Ј,2Ј-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS, Amresco, 200 ml each well) was added. The absorbance at 405 nm was determined in a microtiter plate reader (BIO-RAD Model 550) after 15 to 30 min of incubation at room temperature. The assays were carried out in triplicates. Six HBV positive and three negative serum samples obtained from the General Hospital of Kuala Lumpur, Malaysia, were also tested using the phage-ELISA method. The serum samples (100 ml) were first treated with 50 ml of pretreatment solution {15% sodium dodecyl sulfate (SDS) and 5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfate (CHAPS)} for 30 min at 70°C to release the HBcAg from the virion. For each well, the treated serum samples (120 ml; 1 : 10) were coated overnight at 4°C instead of the purified HBcAg. The concentration of fusion phage used in this assay was 1.0ϫ10 12 pfu/ml.
Enzyme-linked immunosorbent assay (ELISA). As a comparison study to the phage-ELISA, the HBcAg was also detected using an anti-HBcAg monoclonal antibody [mAb clone C1-5, original concentration (8 mg/ml); Chemicon]. Different amount of HBcAg (10 ng to 1 mg; 120 ml) was coated onto U-shaped high binding microtiter plate wells for 16 h and blocked with 10% milk diluent for 2 h at 4°C. The wells were washed three times with TBST and anti-HBcAg mAb (1 : 5,000, 1 : 2,500 and 1 : 1,000; 100 ml) was added for 1 h at room temperature followed by anti-mouse antibody AP-conjugated (1 : 5,000, 100 ml; Chemicon). After 1 h incubation at room temperature, unbound an-tibodies were washed off with TBST and the substrate p-nitro phenyl phosphate (NPP, PIERCE, 200 ml) was added. The absorbance at 405 nm was determined in a microtiter plate reader (BIO-RAD Model 550) after 15 to 30 min of incubation at room temperature. The assays were carried out in triplicates.
Phage-dot blot assay. All the steps in this assay were done in duplicates and carried out at room temperature starting with blotting different concentrations of fusion phage (1.0ϫ10 10 , 1.0ϫ10 11 and 1.0ϫ 10 12 pfu/ml; 5 ml) on a nitrocellulose membrane, dried for 15 min and blocked with 10% milk diluent for 2 h. The membrane was then washed with Phosphate Buffer Saline [PBS; K 2 HPO 4 (20 mM), KH 2 PO 4 (5 mM), NaCl (150 mM)] supplemented with 0.05% Tween 20 (PBST). Different concentrations of purified HBcAg (10 ng to 1 mg; 5 ml) were added and incubated at room temperature for 1 h. After washing three times with PBST, anti-HBcAg monoclonal antibody (Chemicon, 1 : 5,000; 5 ml) was added for 1 h followed by secondary antibody, anti-mouse alkaline phosphatase conjugated (Chemicon, 1 : 5,000; 5 ml) for another hour with gentle agitation. The color development of the blots was observed by adding 5-bromo-4-chloro-indoylphosphate (BCIP) and nitro blue tetrazolium chloride (NBT) substrates (33 ml BCIP and 66 ml NBT in 10 ml alkaline phosphatase buffer) for 5 to 15 min or as soon as the dots were visible. The nitrocellulose membrane was washed with water and left to dry. The HBV positive and HBV negative serum samples were also tested using this method whereby the treated serum samples (1 : 10; 5 ml) were used to substitute the purified HBcAg. Dot blot assay. As a positive control for the phagedot blot assay, a dot blot assay using anti-HBcAg mAb was carried out to detect HBcAg. Different concentrations of HBcAg (10 ng to 1 mg; 5 ml) were blotted on the nitrocellulose membrane dried for 15 min and blocked with 10% milk diluent for 2 h. The membrane was then washed with PBST. Different concentrations of antiHBcAg mAb [Chemicon, 1 : 5,000, 1 : 2,500 and 1 : 1,000; 5 ml; original concentration (8 mg/ml)] were added for 1 h followed by secondary antibody, antimouse alkaline phosphatase conjugated (Chemicon, 1 : 5,000; 5 ml) for another hour. The color development of the blots is as described in the phage-dot blot assay. All the steps were done in duplicates and carried out at room temperature.
Phage-immunoprecipitation assay. The cross-linking of the purified M13 fusion phages that act as ligands with cyanogen bromide (CNBr) activated agarose (SIGMA) were optimized. The CNBr activated agarose in powder form was suspended in 1 mM ice-cold HCl for 30 min, washed with distilled water and sodium hydrogen bicarbonate (NaHCO 3 ) buffer at pH 8.5. The NaHCO 3 was used as the coupling buffer and in the washing steps. A gel : buffer ratio of 1 : 2 gave a suitable suspension for coupling the ligands. The ligands and the swollen gel were mixed and the ligands were immobilized for 2 h at room temperature or overnight at 4°C with gentle stirring on a rotator. The coupled ligands were precipitated with centrifugation at 4,000ϫg for 5 min. Uncouple ligands were collected by gentle aspiration while the immobilized ligands were washed with NaHCO 3 buffer and blocked with 0.2 M glycine pH 8.0 for 2 h at room temperature. The blocking solution was removed by extensive washing with NaHCO 3 buffer 3 times followed by acetate buffer pH 4.0 once and lastly once with NaHCO 3 buffer. Bacterial lysate containing unpurified HBcAg or 2.0 mg/ml purified HBcAg was then added and rolled for 2 h. The immunoprecipitation-complex was recovered by centrifugation, washed with NaHCO 3 buffer for 2 times and analyzed by SDS-PAGE. HBcAg was detected by western blotting as described by Towbin et al. (1979) with some modifications. The antibodies used were anti-HBcAg monoclonal antibody (Chemicon, 1 : 5,000; 10 ml) followed by anti-mouse antibody (Chemicon, 1 : 5,000; 10 ml) for 1 h each. Finally, the bands were developed with BCIP/NBT in alkaline phosphatase buffer [100 mM Tris-Cl (pH 9.5), 100 mM NaCl, 5 mM MgCl 2 ]. As soon as the color developed, the nitrocellulose membrane was washed with water and allowed to dry at room temperature. The optimum concentration of fusion phages that is suitable for immobilization and immunoprecipitation was also determined. The wildtype M13 phage that does not carry any insert on the gpIII protein was also used as ligand for immobilization and immunoprecipitation, which served as a negative control.
Results

Phage-ELISA and ELISA
A phage-ELISA was established by immobilizing purified HBcAg on microtitier plate wells. Then, fusion phage carrying the WSFFSNI sequence was added to interact with the immobilized HBcAg. Anti-HBcAg anti-body conjugated to HRP was added. Finally, the substrate for the enzyme was added to produce measurable color. The concentration of fusion phage required to detect different amount of HBcAg coated on microtiter plate wells was determined. Figure 1(a) shows that 10 12 pfu/ml of phage can detect as low as 10 ng of HBcAg. However, the sensitivity of the assay reduces dramatically when the concentration of the phage used was 10 10 or 10 11 pfu/ml. At these concentrations, a significant reading was observed (A 405 nm ϭ0.304) when HBcAg was more than 500 ng. An ELISA using an anti-HBcAg mAb was performed to compare its sensitivity to that of phage-ELISA. Figure 1(b) shows that the mAb can also detect as low as 10 ng of HBcAg at three different concentrations of mAb [1 : 1,000 (8 mg/ml), 1 : 2,500 (3.2 mg/ml) and 1 : 5,000
(1.6 mg/ml)].
The phage-ELISA can also be used to detect HBcAg in HBV positive serum samples (Fig. 2) . Significant readings were obtained for the HBV positive serum samples compared to those of the negative serum samples.
Phage-dot blot assay and dot blot assay
A phage-dot blot assay was established by immobilizing the phage carrying the WSFFSNI sequence on a nitrocellulose membrane. HBcAg was then added to interact with the immobilized phage. The captured HBcAg was detected by the anti-HBcAg antibody followed by the AP-conjugated secondary antibody. The results showed that 10 12 pfu/ml of phage immobilized on the membrane were able to detect 10 ng of HBcAg ( Fig. 3(a) ). For 10 10 and 10 11 pfu/ml of phage, clear dots were only observed when the amount of HBcAg was more than 500 ng. The results obtained from this assay correspond to those of phage-ELISA assay. As a comparison, anti-HBcAg mAb was used directly to detect HBcAg. The minimum HBcAg that can be detected was 10 ng when 1 : 1,000 and 1 : 2,500 of the anti-HBcAg was used. The amount of HBcAg that can be detected with 1 : 5,000 of anti-HBcAg was 50 ng. All the HBV positive serum samples tested with the phage-dot blot assay produced clear dots (Fig. 4) , indicating the potential of the assay for detecting HBcAg in human serum.
Phage-immunoprecipitation assay
This assay was performed to examine the capability of the fusion phage to be cross-linked to CNBr activated-agarose and to study the potential of the immo- The symbols indicate the concentrations of fusion phage and mAb used. The negative control is the wells coated with 10% milk diluent and carried out using the same steps, which showed negligible detection. Data points are meanϮstandard deviation of triplicate determinations. HBV positive serum samples (PS) were treated and phage-ELISA was carried out. HBV negative serum samples (NS) were also included as negative controls. bilized phage to precipitate HBcAg. Optimization of the coupling reaction revealed that the maximum amount of phage could be cross-linked to 1 g of activated agarose was about 7.0ϫ10 6 pfu/ml. About 1.0ϫ10 5 of phage particles immobilized on 14 mg of agarose was able to precipitate 10 mg of purified HBcAg which gave rise to a band of approximately 22 kDa that can be seen on the polyacrylamide gel stained with Coomassie blue (Fig. 5) . Western blot analysis with anti-HBcAg proved that the 22 kDa band was indeed HBcAg (Fig. 6 ). Unpurified HBcAg in bacterial lysate was also precipitated and a band of about the same size was observed in polyacrylamide gel and western blot (Figs. 5 and 6). As a negative control, a wild-type M13 phage without the insert was also immobilized and used to immunoprecipitate the purified HBcAg and unpurified HBcAg in crude lysate. No band of the expected size was observed (Figs. 5 and 6; lane 5).
Discussion
HBcAg has been one of the most important markers for HBV infections. The nucleocapsid of HBV is composed of either 90 or 120 dimers of HBcAg (Böttcher et al., 1997) that is released in the blood circulation after the process of envelopment in the form of Dane particles. Hence, the quantity of HBcAg would demonstrate the viral load as well as its genomic DNA. The concentration of HBcAg in serum is correlated with the level of HBV-associated DNA (Bredehorst et al., 1985; Kimura et al., 2003) , meaning that HBcAg could be a marker for the viral load. Therefore, HBcAg has a Fig. 3. (a) Detection of HBcAg with fusion phage via phage-dot blot assay. Different concentrations of fusion phage were blotted in duplicates and added with 10 ng to 1 mg of HBcAg. Then, primary, AP-conjugated secondary antibodies and the substrate were used to confirm the detection of HBcAg. The fusion phage was substituted with TBS for the negative controls, which did not show significant results. (b) Detection of HBcAg with anti-HBcAg monoclonal antibody via dot blot assay. Different amount of HBcAg (10 ng to 1 mg) were blotted in duplicates and detected with primary, AP-conjugated secondary antibodies and the substrate was used to confirm the detection of HBcAg. 10% milk diluent was blotted for the negative controls, which did not show significant results. great potential to be further developed into a marker for HBV infection. Monoclonal antibodies for the detection of HBcAg are widely used throughout the world and are available in the market. However, production of monoclonal or polyclonal antibodies raised in cell lines or animals are costly and time consuming, which usually takes months compared to recombinant M13 phage which is cheaper in terms of production and can be rapidly propagated. The purification of the filamentous phage involves lesser steps compared to that of monoclonal antibody. Furthermore, the phage bearing the WSFFSNI sequence interacts tightly to HBcAg with a dissociation constant (K D rel ) less than 25 nM (Ho et al., 2003) . This value indicates that the strength of the interaction between the recombinant phage with HBcAg is as strong as antibody-antigen interaction. Hence, in principle, the phage has the potential to be further developed into a diagnostic reagent.
In this study, a phage-ELISA assay was established and the minimum amount of HBcAg that can be detected was about 10 ng with 1.0ϫ10 12 pfu/ml of the pu- HBV positive serum samples (PS) and HBV negative serum samples (NS) were treated with SDS and CHAPS prior to the assay as described in MATERIALS AND METHODS. rified fusion phage. Results from dot blot assay correspond with those of the phage-ELISA and the amount of HBcAg that can be detected using 10 12 pfu/ml fusion phage was 10 ng. ELISA and dot blot assay was also carried out whereby the HBcAg was directly detected using an anti-HBcAg monoclonal antibody. From the ELISA, the significant minimum amount of HBcAg that can be detected was about 10 ng. The results from dot blot assay also showed that the minimum amount of HBcAg that can be detected was 10 ng when 1 : 1,000 (8 mg/ml) and 1 : 2,500 (3.2 mg/ml) of primary antibody were used.
The newly established phage-ELISA and phage-dot blot assay were used to detect HBcAg in HBV positive serum samples. The positive samples showed significant readings in phage-ELISA, and clear dots on nitrocellulose membranes were observed in the phage-dot blot assay. These results indicate that both assays could be used to detect HBcAg released from the virion.
A method to cross-link the fusion phage carrying the WSFFSNI peptide to agarose using CNBr was developed. The immobilized phage was able to precipitate purified HBcAg and HBcAg in bacterial lysate, demonstrating the potential of the phage as a ligand in purifying HBcAg preferably through affinity chromatography.
In summary, the assays established in this study could be used for the detection and purification of HBcAg. However, more work has to be carried out to study the stability of the phage particle in these assays.
